| Ma, Ding |
L-MOCA, NCT03534453: Olaparib Tablets Maintenance Monotherapy Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy |
|
|
| Active, not recruiting | 3 | 229 | RoW | Olaparib 300mg tablets | AstraZeneca | Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy, Platinum Sensitive | 12/24 | 12/24 | | |
BGB-290-302, NCT03519230: Maintenance Treatment With BGB-290 Versus Placebo in Participants With Platinum-sensitive Recurrent Ovarian Cancer |
|
|
| Active, not recruiting | 3 | 224 | RoW | Pamiparib capsule, BGB-290, Placebo capsule | BeiGene | Ovarian Cancer | 06/25 | 06/26 | | |
|
|
NCT04590599: A Phase II Clinical Study to Assess the Efficacy and Safety of IBI310 or Placebo Combined With Sintilimab for Advanced Cervical Cancer Subjects Who Have Failed or Cannot Tolerate First-line or Above Platinum-based Chemotherapy |
|
|
| Completed | 2 | 205 | RoW | IBI310, Placebo, Sintilimab, IBI308 | Innovent Biologics (Suzhou) Co. Ltd. | Advanced Cervical Cancer | 11/23 | 11/23 | | |
NCT05325229: A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer |
|
|
| Recruiting | 2 | 94 | RoW | Docetaxel for injection (Albumin-bound), Bevacizumab | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Platinum-resistant Recurrent Ovarian Cancer | 12/24 | 12/24 | | |
NCT06336707: HS-20089 Combination Treatment in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 1048 | RoW | HS-20089, Adebrelimab, Bevacizumab, Cisplatin / carboplatin | Hansoh BioMedical R&D Company | Advanced Solid Tumors | 04/26 | 04/28 | | |
| Chen, Gang |
METIS, NCT02831959: Pivotal, Open-label, Randomized Study of Radiosurgery with or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases from Non-small Cell Lung Cancer (NSCLC). |
|
|
| Completed | 3 | 298 | Europe, Canada, US, RoW | NovoTTF-200M device, Best Standard of Care | NovoCure GmbH | Brain Metastases from Non-small Cell Lung Cancer (NSCLC) | 11/24 | 11/24 | | |
NEOPCOSCC, NCT05798793: Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 309 | RoW | Camrelizumab plus TP, SHR-1210 plus Docetaxel, Cisplatin, TP, Docetaxel, Cisplatin | Hospital of Stomatology, Wuhan University, Jiangsu HengRui Medicine Co., Ltd. | Oral Squamous Cell Carcinoma | 07/26 | 10/26 | | |
| Recruiting | 2/3 | 1912 | Canada, US | Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month | NRG Oncology, Natera, Inc., National Cancer Institute (NCI) | Stage III Colon Cancer | 03/29 | 03/30 | | |
| Completed | 2 | 68 | RoW | Camrelizumab, SHR-1210, Camrelizumanb plus TPF, Docetaxel, Cisplatin, 5-Fluorouracil | Hospital of Stomatology, Wuhan University, Jiangsu HengRui Medicine Co., Ltd. | Oral Squamous Cell Carcinoma | 08/22 | 08/24 | | |
NCT05892653: A Study of ABM-1310 in Patients With BRAF V600-Mutant Relapsed and Drug Resistant Primary Malignant Brain Tumors |
|
|
| Terminated | 1 | 15 | RoW | ABM-1310 | ABM Therapeutics Shanghai Company Limited | Primary Malignant Brain Tumor | 08/24 | 08/24 | | |
| Tian, Daishi |
NCT06413654: A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD) |
|
|
| Recruiting | 2/3 | 132 | RoW | B001, Placebo | Shanghai Jiaolian Drug Research and Development Co., Ltd, Shanghai Pharmaceuticals Holding Co., Ltd | Neuromyelitis Optica Spectrum Disorders | 10/27 | 02/29 | | |
NCT06044350: A Clinical Trial of BAT4406F Injection in Patients with Neuromyelitis Optica Spectrum Disorders |
|
|
| Recruiting | 2 | 162 | RoW | BAT4406F Injection, BAT4406F Placebos | Bio-Thera Solutions | Optic Neuromyelitis Spectrum Disease | 05/25 | 05/26 | | |
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
|
|
| Recruiting | 1 | 36 | RoW | CT103A cells, Cyclophosphamide and fludarabine | Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd. | Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome | 02/27 | 05/27 | | |
NCT06612710: The Safety and Efficacy of NouvSoma001 in Ischemic Stroke |
|
|
| Not yet recruiting | 1 | 69 | RoW | extracellular vesicles derived from human induced neural stem cell for intravenous injection, NouvSoma001, a placebo of extracellular vesicles derived from human induced neural stem cell for intravenous injection, NouvSoma001placebo | Tongji Hospital, iRegene Therapeutics Co., Ltd. | Ischemic Stroke | 11/25 | 11/27 | | |
NCT06620809: The Safety and Efficacy of NouvSoma001 in Neuromyelitis Optica Spectrum Disorders |
|
|
| Not yet recruiting | 1 | 69 | RoW | Extracellular vesicles derived from human-induced neural stem cells for intrathecal injection, NouvSoma001, A placebo of extracellular vesicles derived from human-induced neural stem cells for intrathecal injection | Tongji Hospital, iRegene Therapeutics Co., Ltd. | Neuromyelitis Optica Spectrum Disorders | 11/25 | 11/27 | | |
| Wang, Guihua |
AZUR-2, NCT05855200: Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer |
|
|
| Recruiting | 3 | 711 | Europe, Canada, Japan, US, RoW | Dostarlimab, CAPEOX, FOLFOX | GlaxoSmithKline | Colonic Neoplasms, Neoplasms, Colon | 12/28 | 12/30 | | |
| Wang, Qiguang |
IRIS, NCT04973540: A Clinical Trial to Evaluate the Safety and Efficacy of IBS Angel in Patients With Pulmonary Artery Stenosis |
|
|
| Recruiting | N/A | 82 | RoW | Iron Bioresorbable Scaffold System (IBS Angel) | Biotyx Medical (Shenzhen) Co., Ltd. | Pulmonary Artery Stenosis | 07/24 | 12/25 | | |
NCT05774288: Safety and Efficacy of Cera™ Patent Foramen Ovale Occluders. |
|
|
| Recruiting | N/A | 244 | RoW | Cera™ patent foramen ovale occluders, Another patent foramen ovale occluders | Lifetech Scientific (Shenzhen) Co., Ltd. | Patent Foramen Ovale, Cryptogenic Stroke | 04/25 | 06/29 | | |
| Guo, Xiaomei |
| No trials found |
